BIIB Stock Analysis & IQ Rating | Biogen

BIIB Price Performance

BIIB Analysts opinion is negative and it remained unchanged from the past 3 months

Date

Action

Rating

Firm

Nov 22, 2025

Reiterate

Neutral

Piper Sandler

Nov 07, 2025

Upgrade

Buy

Stifel

Nov 01, 2025

Reiterate

Outperform

RBC

Sep 25, 2025

Initiate

Buy

Jefferies

Sep 25, 2025

Upgrade

Neutral

Goldman Sachs

Biogen Inc. (BIIB) Q4 Earnings and Revenues Top Estimates. Biogen (BIIB) delivered earnings and revenue surprises of 23.40% and 3.06% respectively for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Fri Feb 6, 2026

Biogen Q4 Results Top Estimates. Guides FY26 Adj. EPS Above Estimates . (RTTNews) - Biotechnology company Biogen Inc. (BIIB) reported Friday a net loss attributable to the company for the fourth quarter of $48.9 million or $0.33 per share compared to net income of $266.8 million or $1.83 per share in the prior-year quarter.

Fri Feb 6, 2026

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for. Biogen (BIIB) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fri Jan 30, 2026

Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE . (RTTNews) - Biogen Inc. (BIIB) announced Wednesday that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE).

Wed Jan 28, 2026

Biogens Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus a Disease With No Targeted Treatment Options. CAMBRIDGE Mass. Jan. 28 2026 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) – announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE). Litifilimab is a first in-class humanized IgG1 monoclonal antibody (mAb) target

Wed Jan 28, 2026

FDA Grants Priority Review To Eisai And Biogens SBLA For LEQEMBI Subcutaneous Autoinjector . (RTTNews) - Eisai Co. Ltd. (ESALY ESALF 4523.T) and Biogen Inc. (BIIB) announced that the United States Food and Drug Administration has accepted for review Eisais Supplemental Biologics License Application (sBLA) for lecanemab-irmb (United States brand name: LEQEMBI) subcutaneous autoinjector

Mon Jan 26, 2026

FDA Accepts To Priority Review Eisai And Biogens LEQEMBI SBLA For Early Alzheimers Disease . (RTTNews) - Eisai Co. Ltd (4523.T ESALY.PK ESALF.PK) a Japanese commercial-stage biotechnology firm and Biogen Inc. (BIIB) said the United States Food and Drug Administration (FDA) has accepted for priority review Eisais Supplemental Biologics License Application (sBLA) for lecanema

Mon Jan 26, 2026

Looking Into Biogen Incs Recent Short Interest. BIIB) short interest as a percent of float has fallen 32.24% since its last report. According to exchange reported data there are now Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will ...

Fri Jan 23, 2026